ATE511654T1 - Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpern - Google Patents

Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpern

Info

Publication number
ATE511654T1
ATE511654T1 AT03773780T AT03773780T ATE511654T1 AT E511654 T1 ATE511654 T1 AT E511654T1 AT 03773780 T AT03773780 T AT 03773780T AT 03773780 T AT03773780 T AT 03773780T AT E511654 T1 ATE511654 T1 AT E511654T1
Authority
AT
Austria
Prior art keywords
low
antibodies
mab
recruited
antigens
Prior art date
Application number
AT03773780T
Other languages
English (en)
Inventor
Romeuf Christophe De
Christine Gaucher
Arnaud Glacet
Frederic Dhainaut
Dominique Bourel
Nicolas Bihoreau
Emmanuel Nony
Original Assignee
Lfb Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0211415A external-priority patent/FR2844520B1/fr
Priority claimed from FR0211416A external-priority patent/FR2844521B1/fr
Application filed by Lfb Biotechnologies filed Critical Lfb Biotechnologies
Application granted granted Critical
Publication of ATE511654T1 publication Critical patent/ATE511654T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03773780T 2002-09-13 2003-09-15 Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpern ATE511654T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0211415A FR2844520B1 (fr) 2002-09-13 2002-09-13 Utilisation d'un anticorps induisant la secretion de cytokines en therapie
FR0211416A FR2844521B1 (fr) 2002-09-13 2002-09-13 Mesure de la production de cytokines comme marqueur d'activation de cellules effectrices
PCT/FR2003/002715 WO2004024768A2 (fr) 2002-09-13 2003-09-15 Anticorps induisant la production de cytokines

Publications (1)

Publication Number Publication Date
ATE511654T1 true ATE511654T1 (de) 2011-06-15

Family

ID=31995630

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03773780T ATE511654T1 (de) 2002-09-13 2003-09-15 Test für cd16-vermittelte adcc effektivität von monoklonalen oder polklonalen antikörpern

Country Status (9)

Country Link
US (2) US7595165B2 (de)
EP (2) EP2092939A3 (de)
JP (1) JP4368800B2 (de)
AT (1) ATE511654T1 (de)
AU (1) AU2003282161B2 (de)
CA (1) CA2498315C (de)
DK (1) DK1537419T3 (de)
IL (1) IL167385A (de)
WO (1) WO2004024768A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2092939A3 (de) * 2002-09-13 2011-12-21 LFB Biotechnologies Therapeutische Verwendung von Antikörpern, die die Produktion von Zytokinen induzieren
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
FR2895086B1 (fr) * 2005-12-16 2012-10-05 Lab Francais Du Fractionnement Potentialisation de l'apoptose par des anticorps monoclonaux
US20100167315A1 (en) * 2006-09-13 2010-07-01 Glycode Method for investigating the response to a treatment with a monoclonal antibody
FR2968561B1 (fr) † 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
FR3064007A1 (fr) 2017-03-20 2018-09-21 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anticorps pour le traitement de cancers
WO2020168250A1 (en) * 2019-02-14 2020-08-20 Research Institute At Nationwide Children's Hospital Use of a stimulating agent to assay immune cell potency

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059540A1 (en) * 1999-04-05 2000-10-12 Biocrystal Ltd. Assay kits and methods for immune complex-mediated activation involving shed antigens
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
PL213948B1 (pl) * 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
EP2092939A3 (de) * 2002-09-13 2011-12-21 LFB Biotechnologies Therapeutische Verwendung von Antikörpern, die die Produktion von Zytokinen induzieren

Also Published As

Publication number Publication date
EP1537419B1 (de) 2011-06-01
IL167385A (en) 2012-08-30
US20050249732A1 (en) 2005-11-10
WO2004024768A2 (fr) 2004-03-25
JP2006517087A (ja) 2006-07-20
AU2003282161B2 (en) 2010-06-24
US20100323368A1 (en) 2010-12-23
JP4368800B2 (ja) 2009-11-18
EP2092939A3 (de) 2011-12-21
EP2092939A2 (de) 2009-08-26
WO2004024768A3 (fr) 2004-09-30
US7595165B2 (en) 2009-09-29
AU2003282161A1 (en) 2004-04-30
CA2498315A1 (fr) 2004-03-25
CA2498315C (fr) 2013-01-29
EP1537419A2 (de) 2005-06-08
DK1537419T3 (da) 2011-06-27

Similar Documents

Publication Publication Date Title
US8603477B2 (en) Use of anti-CS1 antibodies for treatment of rare lymphomas
MX2022012182A (es) Metodos de uso de anticuerpos anti-trem2.
HRP20191609T1 (hr) Protein
WO2004029092A8 (fr) Anticorps pour adcc et induisant la production de cytokines.
PE20060376A1 (es) ANTICUERPO MONOCLONAL HUMANIZADO O QUIMERICO COMO INHIBIDOR DE hIL-3
AU2005315534B2 (en) Cytotoxic antibody directed against type B lymphoid hematopoietic proliferations
CR20130150A (es) Proteínas de la unión a il-12/p40 (divisional exp. 9599)
LTC2380910I2 (lt) Antigeną surišančios molekulės su padidintu Fc receptoriaus prisirišimo gimingumu ir efektorine funkcija
RU2006144820A (ru) Антитела, связывающиеся с рецепторами kir2dl1,-2,-3 и не связывающиеся с рецептором kir2ds4, и их терапевтическое применение
PL374587A1 (en) Pharmaceutical compositions directed to erb-b1 receptors
RU2008133032A (ru) Антитела к ох-2/сd200 и их применение
UA92504C2 (en) Anti-myostatin monoclonal antibody
PH12021552002A1 (en) Anti-trem2 antibodies and methods of use thereof
EA200601752A1 (ru) Антимиостатиновые антитела
NZ616992A (en) Anti-ilt7 antibody
CN116920085A (zh) 抗-vista（b7h5）抗体
RU2011137369A (ru) Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента
DK0812333T3 (da) Bispecifikt antistof, som er effektivt til behandling af B-cellelymfom og cellelinie
FI973120A0 (fi) Ihmisen gp39:n eri epitoopeille spesifisiä monoklonaalisia vasta-aineita ja menetelmiä niiden käyttämiseksi diagnosoinnissa ja terapiassa
PE20030846A1 (es) Anticuerpos para cd40
ATE488530T1 (de) Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
WO2006133450A3 (en) Anti-cd19 antibody therapy for the transplantation
WO2004108766A3 (en) Anti-hgf-r antibodies and their use
MY137078A (en) Recombinant antibodies associated to gangliosides. their use indiagnosis and treatment of tumors.
ATE526409T1 (de) Humanisierte antikörper spezifisch für sowohl cd45rb als auch cd45ro

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1537419

Country of ref document: EP